Greenland Mines Ltd

Greenland Mines Ltd, previously known as Klotho Neurosciences, Inc., is a biotechnology company focused on developing treatments for chronic illnesses, including neurodegenerative conditions, cancer, and cardiovascular diseases. Its product pipeline centers on proprietary gene and cell therapy candidates, specifically KLTO-101 for Alzheimer's disease and KLTO-202 for amyotrophic lateral sclerosis, which utilize the Klotho protein. Additionally, the company maintains licensed platforms comprising generic pharmaceuticals and biosimilar biologics targeting various solid tumors, and it operates an initiative focused on exploring and mining critical and precious minerals. Its therapeutics target adult and pediatric patient populations suffering from severe chronic disorders.

The company maintains its executive headquarters in Charlotte, North Carolina. Its operational footprint and intellectual property assets span multiple international regions. It holds marketing authorizations for five anti-cancer medications approved for sale in Germany. Furthermore, the organization conducts sponsored scientific research through academic partnerships in Spain and holds patent rights and applications across the United States, Europe, Canada, China, and other global territories.

Summary of the business section of Greenland Mines's latest annual report, written by StockData.